Genprex to Participate at BIO International Convention 2026
Rhea-AI Summary
Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company developing treatments for cancer and diabetes, will attend the BIO 2026 International Convention in San Diego from June 22-25, 2026.
Senior Vice President Thomas Gallagher will hold in-person one-on-one meetings about Genprex's gene therapy programs.
Positive
- None.
Negative
- None.
News Market Reaction – GNPX
In the Jun 17 session, GNPX gained 10.95%, reflecting a significant positive market reaction. Argus tracked a peak move of +37.9% during that session. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Clinical data update | Positive | -6.0% | ASCO biomarker data for Reqorsa in lung cancer patients. |
| May 14 | Preclinical data | Positive | +1.2% | Positive preclinical diabetes gene therapy data at ASGCT. |
| Apr 30 | Patent grant | Positive | +12.1% | Israel patent grant for Reqorsa plus PD-1 antibodies. |
| Apr 28 | Preclinical data | Positive | -0.5% | Announcement of upcoming positive preclinical diabetes data. |
| Apr 22 | Clinical data preview | Positive | -5.4% | Planned release of positive Reqorsa biomarker data at ASCO. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical, preclinical and IP updates often saw mixed to negative next-day moves, suggesting a pattern of weak price response to favorable news.
Over the past few months, Genprex reported multiple positive developments, including biomarker data for Reqorsa at ASCO (Apr 22, May 26), preclinical diabetes gene therapy results at ASGCT (Apr 28, May 14), and an Israel patent grant for Reqorsa combinations (Apr 30). Price reactions ranged from a 12.07% gain on the patent news to declines of about 5–6% after seemingly positive clinical updates. Today’s routine convention-participation announcement comes against this backdrop of mixed market reception.
Key Terms
gene therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World
In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Mr. Gallagher will be available in-person to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes.
For those interested in meeting with Mr. Gallagher or other members of Genprex's management team, please request a meeting through the conference meeting portal or by contacting Investor Relations at investors@genprex.com.
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html
SOURCE Genprex, Inc.